穴位疗法治疗哮病的临床效果及机制(1)
摘要 目的：探討穴位疗法对哮病缓解期患者临床疗效的机制。方法：选取2015年1月至2016年6月武汉市第一医院收治的哮病缓解期患者90例，按随机数字表分为A组、B组、C组，每组30例，A组给予穴位疗法，B组给予穴位注射，C组给予舒利迭治疗，共治疗8周。观察3组患者治疗2个月后(近期)和停止治疗3个月后(远期)的哮喘控制情况(完全控制、部分控制、未控制)以及患者治疗前、治疗2个月后(近期)、停止治疗3个月后(远期)的皮质醇(COR)、T淋巴细胞亚群(CD4+、CD8+、CD4+/CD8+)、白介素5(IL-5)、白介素10(IL-10)的水平，并对3组近远期疗效及COR、CD4+、CD8+、CD4+/CD8+、IL-5、IL-10)的水平进行统计学分析。结果：3组近期疗效，A组治疗有效率(96.67%)明显优于B组(80.00%)和C组(66.67%)(P<0.05)，差异有统计学意义；3组远期疗效，A组治疗有效率(93.33%)明显优于B组(76.67%)和C组(63.33%)(P<0.05)，差异有统计学意义；A组治疗2个月后和停止治疗3个月后的COR、CD4+、CD8+、CD4+/CD8+、IL-5、IL-10的水平与B组、C组同期比较，均有明显改善，差异有统计学意义(P<0.05)。结论：穴位疗法通过补肾、健脾、通肺气可能改善哮病患者COR、CD4+、CD8+、CD4+/CD8+、IL-5、IL-10水平的变化，从而提高临床疗效。
, http://www.100md.com
关键词 穴位疗法；哮病；皮质醇；T淋巴细胞亚群；白介素
Abstract Objective：To explore the clinical effect mechanism of acupoint therapy in patients with asthma at remission stage. Methods：A total of 90 patients with asthma at remission stage who were admitted and treated in Wuhan First Hospital from January 2015 to June 2016 were selected and divided into group A (acupoint therapy)， group B (acupoint injection) and group C (seretide) according to the random number table with 30 cases in each group. The treatment last 8 weeks. The asthma control situation (full control， portion control， no control) after two months′ treatment (short-term) and 3 months after stopping treatment (long-term)， and cortisol (COR)， Interleukin-5 (IL-5)， Interleukin-10 (IL-10)， T lymphocytes (CD4+， CD8+， CD4+/CD8+) before treatment， after two months′ treatment (short-term) and 3 months after stopping treatment (long-term) of patients in three groups were observed， and clinical efficacy in short-term and long-term， as well as the levels of COR， CD4+， CD8+， CD4+/CD8+， IL-5 and IL-10 in the three groups were statistically analyzed. Results：In short-term efficacy， the total effective rate of group A (96.67%) was significantly better than group B (80.00%) and group C (66.67%) with statistical significance (P<0.05)； In long-term efficacy， the total effective rate of group A (93.33%) was significantly better than group B (76.67%) and group C (63.33 %) with statistical significance (P<0.05)； Compared with group B and group C， the levels of COR， CD4+， CD8+， CD4+/CD8+， IL-5 and IL-10 in group A were significantly improved with statistical significance (P<0.05). Conclusion：Acupoint therapy may improve the changes of COR， CD4+， CD8+， CD4+/CD8+， IL-5， IL-10 in patients with asthma by supplementing the kidney， strengthening the spleen and smoothing the lungs， so as to improve the clinical curative effect., 百拇医药(梁亚光 李斌 谢俊刚 尹莹 罗光伟 贾珉 莫松雅 黄白银)
, http://www.100md.com
关键词 穴位疗法；哮病；皮质醇；T淋巴细胞亚群；白介素
Abstract Objective：To explore the clinical effect mechanism of acupoint therapy in patients with asthma at remission stage. Methods：A total of 90 patients with asthma at remission stage who were admitted and treated in Wuhan First Hospital from January 2015 to June 2016 were selected and divided into group A (acupoint therapy)， group B (acupoint injection) and group C (seretide) according to the random number table with 30 cases in each group. The treatment last 8 weeks. The asthma control situation (full control， portion control， no control) after two months′ treatment (short-term) and 3 months after stopping treatment (long-term)， and cortisol (COR)， Interleukin-5 (IL-5)， Interleukin-10 (IL-10)， T lymphocytes (CD4+， CD8+， CD4+/CD8+) before treatment， after two months′ treatment (short-term) and 3 months after stopping treatment (long-term) of patients in three groups were observed， and clinical efficacy in short-term and long-term， as well as the levels of COR， CD4+， CD8+， CD4+/CD8+， IL-5 and IL-10 in the three groups were statistically analyzed. Results：In short-term efficacy， the total effective rate of group A (96.67%) was significantly better than group B (80.00%) and group C (66.67%) with statistical significance (P<0.05)； In long-term efficacy， the total effective rate of group A (93.33%) was significantly better than group B (76.67%) and group C (63.33 %) with statistical significance (P<0.05)； Compared with group B and group C， the levels of COR， CD4+， CD8+， CD4+/CD8+， IL-5 and IL-10 in group A were significantly improved with statistical significance (P<0.05). Conclusion：Acupoint therapy may improve the changes of COR， CD4+， CD8+， CD4+/CD8+， IL-5， IL-10 in patients with asthma by supplementing the kidney， strengthening the spleen and smoothing the lungs， so as to improve the clinical curative effect., 百拇医药(梁亚光 李斌 谢俊刚 尹莹 罗光伟 贾珉 莫松雅 黄白银)
参见：首页 > 医疗版 > 症状 > X > 哮病